Literature DB >> 11732871

Relationship between bone marrow angiogenesis and plasma cell infiltration and serum beta2-microglobulin levels in patients with multiple myeloma.

O Sezer1, K Niemöller, C Jakob, I Zavrski, U Heider, J Eucker, O Kaufmann, K Possinger.   

Abstract

There is growing evidence that angiogenesis is important not only in solid tumors but also in hematological malignancies. Recently, we found that bone marrow angiogenesis is a prognostic factor for disease-related survival in patients with multiple myeloma. In this report, we addressed the question of whether the microvessel density in bone marrow biopsies is correlated to other myeloma parameters, e.g., serum beta2-microglobulin (beta2-MG) and plasma cell infiltration in the bone marrow. In 22 multiple myeloma patients, immunohistochemical, CD34-stained, paraffin-embedded bone marrow biopsies before and after chemotherapy were studied. Microvessels were counted in 400x magnification, and the mean number of vessels per area in each sample was noted as the microvessel density (MVD). Pretreatment bone marrow MVD (median: 44, range: 11-175 vessels/mm2) correlated significantly with the bone marrow plasma cell infiltration (median: 30%, range: 5-90%, r = 0.642, P=0.001) and beta2-MG (median: 2.74, range: 1.4-26.1 mg/l, r = 0.749, P < 0.0005). In contrast, there was no correlation between posttreatment MVD and plasma cell infiltration or beta2-MG (median: MVD 31, range: 0-221 vessels/mm2, median plasma cell infiltration: 15%, range: 5-80%, r = 0.229, P = 0.306 and median beta2-MG: 2.65, range: 1-27.6 mg/l, r = -0.042, P = 0.853). These findings show that the strong correlations between bone marrow MVD and plasma cell infiltration as well as serum beta2-MG levels disappear after chemotherapy. The underlying mechanisms need further investigations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11732871     DOI: 10.1007/s002770100361

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  10 in total

1.  Multiple myeloma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2004-01-14       Impact factor: 3.909

2.  Angiogenesis and multiple myeloma.

Authors:  Nicola Giuliani; Paola Storti; Marina Bolzoni; Benedetta Dalla Palma; Sabrina Bonomini
Journal:  Cancer Microenviron       Date:  2011-07-07

Review 3.  Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma.

Authors:  Julie C Dutoit; Koenraad L Verstraete
Journal:  Skeletal Radiol       Date:  2017-03-13       Impact factor: 2.199

4.  Immunohistochemical expression of endoglin offers a reliable estimation of bone marrow neoangiogenesis in multiple myeloma.

Authors:  Michael G Alexandrakis; Ioannis K Neonakis; Constantina A Pappa; Ioannis Konsolas; Maria Kokonozaki; Rodanthi Vyzoukaki; Stella Soundoulounaki; Athina Xekalou; Katerina Sfiridaki; George Tsirakis
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-13       Impact factor: 4.553

5.  Diffusion-weighted imaging (DWI) in diagnosis, staging, and treatment response assessment of multiple myeloma: a systematic review and meta-analysis.

Authors:  Pooya Torkian; Bahar Mansoori; Jens Hillengass; Javid Azadbakht; Sina Rashedi; Sarah S Lee; Behrang Amini; Pietro Andrea Bonaffini; Majid Chalian
Journal:  Skeletal Radiol       Date:  2022-07-26       Impact factor: 2.128

Review 6.  Multiple myeloma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2010-02-11       Impact factor: 3.909

7.  The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma.

Authors:  M G Alexandrakis; F H Passam; C Dambaki; C A Pappa; E N Stathopoulos
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

8.  Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells.

Authors:  S Lamorte; S Ferrero; S Aschero; L Monitillo; B Bussolati; P Omedè; M Ladetto; G Camussi
Journal:  Leukemia       Date:  2011-10-25       Impact factor: 11.528

9.  Problems monitoring response in multiple myeloma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2005-11-23       Impact factor: 3.909

10.  Plasma Levels of Monocyte Chemotactic Protein-1 Are Associated with Clinical Features and Angiogenesis in Patients with Multiple Myeloma.

Authors:  Toni Valković; Emina Babarović; Ksenija Lučin; Sanja Štifter; Merica Aralica; Irena Seili-Bekafigo; Antica Duletić-Načinović; Nives Jonjić
Journal:  Biomed Res Int       Date:  2016-01-27       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.